BrightSpring Health Services(US:BTSG)2026-02-27 14:32Financial Data and Key Metrics Changes - For Q4 2025, total company revenue was $3.6 billion, representing a 29% increase year-over-year [25] - Full year 2025 total revenue reached $12.9 billion, reflecting a 28% growth compared to 2024 [28] - Adjusted EBITDA for Q4 was $184 million, up 41% from the previous year, while full year adjusted EBITDA was $618 million, a 34% increase [29] - The adjusted EBITDA margin for the company was 4.8%, a 20 basis point increase from 2024 [11] Business Line Data and Key Metrics Changes - Pharmacy Solutions segment revenue in Q4 was $3.2 billion, achieving 32% year-over-year growth [25] - Provider Services segment revenue for Q4 was $394 million, representing a 13% increase compared to the prior year [26] - Home Health care revenue grew 19% year-over-year to $217 million in Q4 [27] - Rehab revenue increased by 8% year-over-year, while personal care revenue grew 4% [27] Market Data and Key Metrics Changes - Home health care represented approximately 55% of revenue in the Provider Services segment, with an average daily census growth of 15% [21] - Specialty and infusion script growth was 30% year-over-year in Q4, with total pharmacy script volume at 10.8 million [17] - The company expects to see continued growth in home health, hospice, and infusion markets over the next five to ten years [50] Company Strategy and Development Direction - The company plans to divest the community living business to streamline operations and focus on core patient populations [6] - The acquisition of Amedisys and LHC Home Health Assets is expected to enhance the company's home health capabilities [7] - BrightSpring aims to build a unique and scaled home and community healthcare platform that demonstrates leading quality outcomes [10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future of home health and hospice, citing a strong runway for growth [50] - The company anticipates total revenue growth of approximately 14% year-over-year for 2026, with adjusted EBITDA expected to grow by about 25% [13] - Management highlighted the importance of executing sales investments and operational efficiencies to drive volume growth [38] Other Important Information - The company achieved a leverage ratio of 2.99x as of December 31, 2025, down from 4.16x the previous year [32] - The expected net cash proceeds from the community living sale are approximately $715 million, which will primarily be used for debt paydown [33] Q&A Session Summary Question: Variability in 2026 Outlook - Management noted consistency in Q1 and emphasized the importance of executing strategies to drive volume growth across businesses [37][38] Question: LDD Introductions and Landscape - Management confirmed expectations for 16-20 new LDD introductions over the next 12-18 months, with a focus on quality and service [40][41] Question: EBITDA and Margins by Segment - Management indicated broad-based margin expansion is expected due to operational efficiencies and favorable product mix [45][46] Question: Home Health Rate Environment - Management remains optimistic about home health rates, projecting a flat baseline with potential for future increases [50] Question: Specialty Drug Launches and Margins - Management highlighted the multifactorial growth in specialty pharmacy, including brand LDDs and generic conversions, which improve margins [56] Question: Amedisys Asset Margins - Management acknowledged the lower margin profile of the Amedisys assets but expressed confidence in improving margins through integration [61][62] Question: Pharmacy Revenue Guidance Components - Management outlined expected revenue headwinds from IRA impacts and brand-to-generic conversions, but still anticipates strong growth across pharmacy businesses [70][71] Question: Infusion Business Update - Management reported double-digit growth in the infusion business and plans for significant expansion in specialty hubs [73][75]